Document is current
Any future updates will be listed below
-
Authors
Merikle, Elizabeth
Presnall, Carrie
Feaster, Todd
Moxon, Robyn
Siemers, Eric
Kerwin, Diana
Cline, Stephanie
-
Funding
Funding for this research was provided by:
Acumen Pharmaceuticals
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 13 March 2026
First Online: 23 March 2026
Declarations
:
: The INTERCEPT-AD phase 1 clinical study was conducted in accordance with International Council for Harmonisation E6 Good Clinical Practice, the Declaration of Helsinki, and all other applicable regulatory requirements. The protocol and informed consent form were approved by ethics committees for all study sites. All participants provided written informed consent.
: The informed consent document, which was signed by all study participants, included permission for the inclusion of their data in the publication of summary data from the INTERCEPT-AD clinical trial.
: CP and EM were employees of Fortrea, Inc. at the time of study conduct; Fortrea, Inc. received funding from Acumen Pharmaceuticals, Inc. for the conduct of this study.DK is the Founder and President of Kerwin Medical Center, which received contractual payments from Acumen Pharmaceuticals, Inc. as an INTERCEPT-AD study site.TF, RM, and ES are employees of and hold equity in Acumen Pharmaceuticals, Inc.SC is a consultant to Acumen Pharmaceuticals, Inc.
